Get the Stockscreener App
3.61
6.96%
-0.27
Genenta Science Spa Adr stock is traded at $3.61, with a volume of 2,332.
It is down -6.96% in the last 24 hours and down -6.48% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$3.88
Open:
$3.8
24h Volume:
2,332
Relative Volume:
0.10
Market Cap:
$66.03M
Revenue:
-
Net Income/Loss:
$-12.63M
P/E Ratio:
-5.2002
EPS:
-0.6942
Net Cash Flow:
$-12.18M
1W Performance:
-9.07%
1M Performance:
-6.48%
6M Performance:
-17.95%
1Y Performance:
+9.07%
1-Day Range:
$3.61
$3.90
1-Week Range:
$3.61
$4.15
52-Week Range:
$2.20
$7.28
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
3.61 | 66.03M | 0 | -12.63M | -12.18M | -0.6942 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Genenta secures $21.9 million for cancer drug trial By Investing.com - Investing.com South Africa
Genenta secures €20M in mandatory convertible bond deal - Investing.com India
Genenta secures €20M in mandatory convertible bond deal By Investing.com - Investing.com South Africa
Genenta secures $21.9 million for cancer drug trial - Investing.com India
Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research - TipRanks
Genenta Science announces amendment to pact with AGC Biologics - Yahoo Finance
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing - GlobeNewswire Inc.
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
Genenta Science Updates ATM Sales Agreement with New Agent - TipRanks
Genenta Science SPA (ADR) trading resumes - TipRanks
Genenta Science SPA (ADR) trading halted, volatility trading pause - TipRanks
3 US Penny Stocks With Market Caps Over $30M To Consider - Yahoo Finance
Genenta Science CEO to present at U.S. Senate meeting - TipRanks
Genenta Science receives Buy rating amid trial approval - Investing.com
Genenta Science Announces Shareholder Meeting - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
DHR Stock Quote Price and Forecast - CNN
Danaher (DHR) Stock Price, News & Analysis - MarketBeat
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):